VivoSeq
Metabolic & Endocrine

Overweight and Obesity

1

Pipeline Programs

4

Active Trials

3

Companies Involved

Overweight and Obesity is an early-stage landscape with 1 program across 3 companies. The most active players are AstraZeneca, Eli Lilly, Midwest Center for Metabolic and Cardiovascular Research.

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

Preclinical1
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Trial Status

11

clinical trials

Completed7 · 64%
Recruiting2 · 18%
Enrolling by invitation1 · 9%
Active, not recruiting1 · 9%

Trial Activity

11 trials

Breathing & Blood Pressure
Recruiting·FFlorida State University·N/A·NCT05632406·80 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)